3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
2
Urothelial Cancer
1
Solid Tumors, KRAS Mutation
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Radiotherapy
3
Radiation
3
palbociclib
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Doxorubicin
2
zimberelimab
1
talimogene laherparepvec
1
sotigalimab
1
ribociclib
1
pazopanib
1
eribulin
1
enzalutamide
1
durvalumab
1
cemiplimab
1
abemaciclib
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Nivolumab
1
Midazolam
1
Letrozole
1
Ipilimumab
1
Ifosfamide
1
Fulvestrant
1
Everolimus
1
Disulfides
1
CTLA-4 Antigen
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Liposarcoma
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled